INT 0022

Drug Profile

INT 0022

Alternative Names: INT-0022; INT0022/2010

Latest Information Update: 23 Dec 2013

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator IntelGenx Corp.
  • Class
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Bipolar disorders

Most Recent Events

  • 12 Dec 2013 No development reported - Phase-I for Bipolar disorders in Canada (PO)
  • 14 Jun 2011 INT 0022 licensed to RedHill BioPharma worldwide
  • 07 Feb 2011 Phase-I clinical trials in Bipolar disorders in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top